S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
S&P 500   4,591.67 (+1.17%)
DOW   35,227.03 (+1.87%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:TBPH

Theravance Biopharma Stock Forecast, Price & News

$7.81
+0.04 (+0.51%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.67
$7.95
50-Day Range
$6.77
$9.05
52-Week Range
$6.10
$22.74
Volume
643,645 shs
Average Volume
650,146 shs
Market Capitalization
$575.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.77
30 days | 90 days | 365 days | Advanced Chart
Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Theravance Biopharma logo

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Headlines

Theravance Biopharma (NASDAQ:TBPH) Stock Price Down 5.5%
December 2, 2021 |  americanbankingnews.com
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down to $8.40
December 1, 2021 |  americanbankingnews.com
Top 10 Stock Picks of Eli Samaha’s Madison Avenue Partners
November 25, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TBPH
Previous Symbol
NASDAQ:TBPHV
Fax
N/A
Employees
359
Year Founded
N/A

Sales & Book Value

Annual Sales
$71.86 million
Book Value
($4.39) per share

Profitability

Net Income
$-278.02 million
Net Margins
-382.14%
Pretax Margin
-397.03%

Debt

Price-To-Earnings

Miscellaneous

Free Float
69,129,000
Market Cap
$575.58 million
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

MarketRank

Overall MarketRank

2.11 out of 5 stars

Medical Sector

502nd out of 1,390 stocks

Pharmaceutical Preparations Industry

234th out of 673 stocks

Analyst Opinion: 4.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

Is Theravance Biopharma a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Theravance Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
View analyst ratings for Theravance Biopharma
or view top-rated stocks.

How has Theravance Biopharma's stock been impacted by COVID-19?

Theravance Biopharma's stock was trading at $24.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TBPH shares have decreased by 68.5% and is now trading at $7.81.
View which stocks have been most impacted by COVID-19
.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Theravance Biopharma
.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.12. The biopharmaceutical company earned $13.19 million during the quarter, compared to analysts' expectations of $13.55 million. During the same quarter in the previous year, the business posted ($1.16) EPS.
View Theravance Biopharma's earnings history
.

What price target have analysts set for TBPH?

8 brokers have issued 12-month price objectives for Theravance Biopharma's stock. Their forecasts range from $7.00 to $18.00. On average, they expect Theravance Biopharma's stock price to reach $10.88 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts' price targets for Theravance Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the following people:
  • Rick E. Winningham, Chairman & Chief Executive Officer
  • Andrew Asa Hindman, Chief Financial Officer & Senior Vice President
  • Vijay Sabesan, Senior Vice President-Technical Operations
  • Philip D. Worboys, Senior VP-Research & Translational Science
  • Bradford J. Shafer, Secretary, Executive VP & General Counsel

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.95%), Madison Avenue Partners LP (6.69%), Point72 Asset Management L.P. (4.62%), Camber Capital Management LP (3.39%), Geode Capital Management LLC (0.95%) and Clearline Capital LP (0.78%). Company insiders that own Theravance Biopharma stock include Brett K Haumann, Philip D Worboys, Richard A Graham and Vijay Sabesan.
View institutional ownership trends for Theravance Biopharma
.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Russell Investments Group Ltd., Laurion Capital Management LP, Geode Capital Management LLC, Macquarie Group Ltd., New York State Common Retirement Fund, Caption Management LLC, and Royal Bank of Canada. Company insiders that have sold Theravance Biopharma company stock in the last year include Philip D Worboys, and Richard A Graham.
View insider buying and selling activity for Theravance Biopharma
or view top insider-selling stocks.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was bought by a variety of institutional investors in the last quarter, including Madison Avenue Partners LP, Point72 Asset Management L.P., Camber Capital Management LP, BlackRock Inc., Clearline Capital LP, Voloridge Investment Management LLC, AXA S.A., and Tri Locum Partners LP.
View insider buying and selling activity for Theravance Biopharma
or or view top insider-buying stocks.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $7.81.

How much money does Theravance Biopharma make?

Theravance Biopharma has a market capitalization of $575.58 million and generates $71.86 million in revenue each year. The biopharmaceutical company earns $-278.02 million in net income (profit) each year or ($3.44) on an earnings per share basis.

How many employees does Theravance Biopharma have?

Theravance Biopharma employs 359 workers across the globe.

What is Theravance Biopharma's official website?

The official website for Theravance Biopharma is www.theravance.com.

Where are Theravance Biopharma's headquarters?

Theravance Biopharma is headquartered at UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.